3/11, 9:17 AM (Source: TeleTrader)
more TeleTrader news

Vir, GSK's treatment cuts deaths, hospitalizations by 85%

Vir Biotechnology Inc. and GlaxoSmithKline plc (GSK) stated on Thursday that their coronavirus antibody treatment has shown 85% efficacy in curbing the number of deaths and hospitalizations in COVID patients at high risk of hospitalization.

While the two companies announced that the trial is planned to include 1,300 participants, the 85% efficacy rate was determined via an interim analysis of data from 583 patients.

Vir and GSK unveiled that the VIR-7831 monoclonal antibody treatment was "well tolerated" by the participants, and announced the plans to conduct an "in vitro study" aimed to determine whether the treatment shows the same effectiveness versus the COVID strains originally uncovered in the United Kingdom, Brazil and South Africa.

Breaking the News / BU